Silence Therapeutics’ (SLN) Outperform Rating Reaffirmed at William Blair

William Blair reiterated their outperform rating on shares of Silence Therapeutics (NASDAQ:SLN) in a report released on Tuesday,RTT News reports.

Several other equities analysts have also issued reports on the stock. Jefferies Financial Group began coverage on shares of Silence Therapeutics in a report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target on the stock. Chardan Capital reissued a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, November 15th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a report on Tuesday, October 8th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Stock Performance

SLN stock opened at $7.68 on Tuesday. Silence Therapeutics has a one year low of $5.81 and a one year high of $27.72. The firm has a market cap of $229.86 million, a price-to-earnings ratio of -4.89 and a beta of 1.30. The firm has a 50-day simple moving average of $17.13 and a two-hundred day simple moving average of $18.78.

Institutional Trading of Silence Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SLN. Redmile Group LLC acquired a new stake in Silence Therapeutics during the first quarter worth about $43,798,000. Eventide Asset Management LLC acquired a new position in shares of Silence Therapeutics in the 3rd quarter valued at $11,635,000. Janus Henderson Group PLC purchased a new stake in Silence Therapeutics during the first quarter worth $13,575,000. First Turn Management LLC acquired a new stake in Silence Therapeutics during the second quarter valued at $10,209,000. Finally, Millennium Management LLC increased its holdings in Silence Therapeutics by 91.2% in the second quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock valued at $14,876,000 after buying an additional 373,523 shares in the last quarter. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.